Posts Tagged ‘obesity’

It seems like some good news is overdue for Novo Nordisk. So the topline report of a phase two study with amycretin that looks like a plausible win is especially welcome. The results at hand come from a 36-week placebo controlled study with a wide range of oral and injection doses in persons with type […]

The sprint to the finish for orforglipron is picking up pace with a pivotal trial in obesity and diabetes published yesterday in The Lancet. Things are looking good for this relatively simple GLP-1 agonist in a tablet. The presentation of these results from ATTAIN-2 were a highlight of ObesityWeek earlier this month, but having this […]

Anyone who thought this would be a passing thing was way off the mark. As prices of GLP-1 medicines are falling, their use is rising. As Stat News notes, we now have more people using these medicines than the entire population of Texas. This rising trend occurs against a background of costs that are still […]

Tired, poor, huddled masses, yearning to breathe free? Those words are “inoperative” now in the U.S. State Department. New guidance from the top suggests America doesn’t want people with obesity getting a visa enter the country. Secretary of State Marco Rubio has issued a directive to U.S. embassy and consular officials all over the world, […]

It would be odd to think that medical schools would stigmatize the most prevalent chronic disease that medical students will encounter. But stigmatizing obesity in medical schools is all too common, even today. Kofi Essel and colleagues published a study of the obesity bias observed by third year medical students at George Washington University School […]

This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]

Just skimming headlines about new medicines for obesity and surgery, comparisons seem to be a dominant theme. Some of these headlines tell us surgery is more cost-effective or delivers more durable results. Some of that is certainly true. But the deeper truth surfaces this week in JAMA and JAMA Network Open. Clinical experience and, increasingly, […]

At a press event last week, announcing a deal to make obesity medicines more affordable, CMS Administrator Mehmet Oz told us “Americans will lose 135 billion pounds by the midterms” because of this. Comedian Stephen Colbert pointed out a problem with the numbers. They imply that every single American will be losing 393 pounds. It […]

This has been quite a week and the ideas we take home from ObesityWeek 2025 come from both inside and outside of the event in Atlanta. It is a reflection of the fact that the work of cloistered insiders in obesity is and will continue to have large effects in the larger world outside of […]

At ObesityWeek in Atlanta, people are speculating about innovations that health professionals in general practice can embrace widely. We’re getting a good look at two candidates to become the GP GLP-1. Providing real obesity care and prescribing these medicines for more than a small portion of patients who need them is far from the norm. […]